<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696939</url>
  </required_header>
  <id_info>
    <org_study_id>2020LY032</org_study_id>
    <nct_id>NCT04696939</nct_id>
  </id_info>
  <brief_title>Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients</brief_title>
  <official_title>Clinical Study of Programmed Cell Death Ligand-1(PD-L1) Antibody (Atezolizumab) Plus Chemotherapy (Carboplatin Plus Etoposide) for Previously Untreated Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II study was designed to evaluate the safety and efficacy of Atezolizumab in&#xD;
      combination with Chemotherapy compared with treatment with Chemotherapy alone in previously&#xD;
      untreated Limited-Stage Small Cell Lung Cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II study was designed to evaluate the safety and efficacy of Atezolizumab in&#xD;
      combination with Chemotherapy (Carboplatin plus Etoposide) compared with treatment with&#xD;
      Chemotherapy (Carboplatin plus Etoposide) alone in previously untreated Limited-Stage Small&#xD;
      Cell Lung Cancer patients. Participants will be divided in a 1:1 ratio to receive either&#xD;
      Atezolizumab + Carboplatin + Etoposide or Carboplatin + Etoposide followed by radical&#xD;
      surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival（DFS）</measure>
    <time_frame>12 months</time_frame>
    <description>To assess disease free survival（DFS）after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>3 months</time_frame>
    <description>To assess disease control rate (DCR) after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>To estimate overall survival (OS) of patients with ES-SCLC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate objective response rate (ORR)after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate duration of response (DOR) after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major pathological response (MPR)</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate major pathological response (MPR) after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete pathological response (CPR）</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate complete pathological response (CPR）after treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <condition>Neoadjuvant Therapy</condition>
  <arm_group>
    <arm_group_label>Atezolizumab + Carboplatin +Etoposide +surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant therapy: Atezolizumab, 1200 milligrams(mg) on Day 1 of every 21-day cycle, 2 cycles; Carboplatin, 75 mg per square meter(mg/m^2) on Day 1 of every 21-day cycle, 2 cycles; Etoposide, 100 mg/m^2 on Day 1 of every 3-day cycle, 2 cycles.&#xD;
Surgery: patients will receive surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin +Etoposide +surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant therapy: Carboplatin, 75 mg/m^2 on Day 1 of every 21-day cycle, 2 cycles; Etoposide, 100 mg/m^2 on Day 1 of every 3-day cycle, 2 cycles.&#xD;
Surgery: patients will receive surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab intravenous infusion was administered at a dose of 1200mg on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Atezolizumab + Carboplatin +Etoposide +surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin intravenous infusion was administered at a dose of 75mg/m^2 on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Atezolizumab + Carboplatin +Etoposide +surgery</arm_group_label>
    <arm_group_label>Carboplatin +Etoposide +surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Day 1 of every 3-day cycle.</description>
    <arm_group_label>Atezolizumab + Carboplatin +Etoposide +surgery</arm_group_label>
    <arm_group_label>Carboplatin +Etoposide +surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be volunteered to participate in the clinical trial. Patients must sign&#xD;
             the informed Consent form (ICF) and be willing to follow and able to complete all test&#xD;
             procedures.&#xD;
&#xD;
          2. Histologically or cytologically confirmed stage IIb-IIIb SCLC.&#xD;
&#xD;
          3. Patients with good physical condition and good organ function.&#xD;
&#xD;
          4. Previously untreated patients.&#xD;
&#xD;
          5. Patients must have measurable disease based on Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) 1.1&#xD;
&#xD;
          6. Patients can tolerate chemotherapy, immunotherapy, and surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unclear diagnosis of SCLC.&#xD;
&#xD;
          2. Contraindicated chemotherapy, immunotherapy, and surgery.&#xD;
&#xD;
          3. Undergoing other active malignancies within 5 years or at the same time.Patients with&#xD;
             localized curable tumors, such as basal cell carcinoma, squamous cell carcinoma,&#xD;
             superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ,&#xD;
             or breast carcinoma in situ, will not be excluded.&#xD;
&#xD;
          4. Positive test result for human immunodeficiency virus (HIV).&#xD;
&#xD;
          5. Positive test result for active tuberculosis.&#xD;
&#xD;
          6. Pregnant or lactating women&#xD;
&#xD;
          7. A history of psychotropic substance abuse, drug abuse, or alcoholism.&#xD;
&#xD;
          8. Other factors assessed by the sponsors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Zhang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Tongji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yayi He, Doctor</last_name>
    <phone>+86-21-65115006</phone>
    <phone_ext>3056</phone_ext>
    <email>2250601@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yayi He, Doctor</last_name>
      <phone>+86-21-65115006</phone>
      <email>2250601@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.</citation>
    <PMID>31590988</PMID>
  </reference>
  <reference>
    <citation>Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.</citation>
    <PMID>30280641</PMID>
  </reference>
  <reference>
    <citation>Yang CJ, Chan DY, Shah SA, Yerokun BA, Wang XF, D'Amico TA, Berry MF, Harpole DH Jr. Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer. Ann Surg. 2018 Dec;268(6):1105-1112. doi: 10.1097/SLA.0000000000002287.</citation>
    <PMID>28475559</PMID>
  </reference>
  <reference>
    <citation>Yang CJ, Chan DY, Speicher PJ, Gulack BC, Tong BC, Hartwig MG, Kelsey CR, D'Amico TA, Berry MF, Harpole DH. Surgery Versus Optimal Medical Management for N1 Small Cell Lung Cancer. Ann Thorac Surg. 2017 Jun;103(6):1767-1772. doi: 10.1016/j.athoracsur.2017.01.043. Epub 2017 Apr 25.</citation>
    <PMID>28385378</PMID>
  </reference>
  <reference>
    <citation>Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F; CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017 Aug;18(8):1116-1125. doi: 10.1016/S1470-2045(17)30318-2. Epub 2017 Jun 20.</citation>
    <PMID>28642008</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Yayi He</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Limited-Stage Small Cell Lung Cancer</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Etoposide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

